Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Neurones Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Neurones has a total shareholder equity of €399.0M and total debt of €11.2M, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are €679.4M and €280.5M respectively. Neurones's EBIT is €73.6M making its interest coverage ratio -10.7. It has cash and short-term investments of €268.1M.
Anahtar bilgiler
2.8%
Borç/özkaynak oranı
€11.21m
Borç
| Faiz karşılama oranı | -10.7x |
| Nakit | €268.12m |
| Eşitlik | €398.95m |
| Toplam yükümlülükler | €280.50m |
| Toplam varlıklar | €679.45m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
What Neurones S.A.'s (EPA:NRO) P/E Is Not Telling You
Jul 27
Returns On Capital At Neurones (EPA:NRO) Have Hit The Brakes
Apr 26Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement
Dec 01If EPS Growth Is Important To You, Neurones (EPA:NRO) Presents An Opportunity
May 18Neurones' (EPA:NRO) Returns Have Hit A Wall
Feb 10Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement
Oct 26Does Neurones (EPA:NRO) Deserve A Spot On Your Watchlist?
Sep 22Neurones (EPA:NRO) Will Pay A Smaller Dividend Than Last Year
Apr 28Should You Be Adding Neurones (EPA:NRO) To Your Watchlist Today?
Jan 25Returns At Neurones (EPA:NRO) Appear To Be Weighed Down
Jan 06Returns On Capital At Neurones (EPA:NRO) Paint A Concerning Picture
Jul 20Is Neurones S.A. (EPA:NRO) Trading At A 25% Discount?
May 06Some Investors May Be Worried About Neurones' (EPA:NRO) Returns On Capital
Mar 24Neurones S.A.'s (EPA:NRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 09The Neurones (EPA:NRO) Share Price Has Gained 54% And Shareholders Are Hoping For More
Feb 16Here's Why Neurones's (EPA:NRO) Statutory Earnings Are Arguably Too Conservative
Jan 25What Percentage Of Neurones S.A. (EPA:NRO) Shares Do Insiders Own?
Jan 11Should Neurones S.A. (EPA:NRO) Be Part Of Your Dividend Portfolio?
Dec 28
Are Neurones S.A. (EPA:NRO) Investors Paying Above The Intrinsic Value?
Dec 15What We Learned About Neurones' (EPA:NRO) CEO Pay
Dec 02Investors Who Bought Neurones (EPA:NRO) Shares Five Years Ago Are Now Up 39%
Nov 17Neurones (EPA:NRO) Is Growing Earnings But Are They A Good Guide?
Jun 30Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: NRO's short term assets (€546.3M) exceed its short term liabilities (€243.4M).
Uzun Vadeli Yükümlülükler: NRO's short term assets (€546.3M) exceed its long term liabilities (€37.1M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: NRO has more cash than its total debt.
Borcun Azaltılması: NRO's debt to equity ratio has increased from 0% to 2.8% over the past 5 years.
Borç Kapsamı: NRO's debt is well covered by operating cash flow (554.5%).
Faiz Kapsamı: NRO earns more interest than it pays, so coverage of interest payments is not a concern.